Pharmacopsychiatry 2014; 47(01): 33-36
DOI: 10.1055/s-0033-1358393
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Are Serotonergic System Genes Associated to Smoking Cessation Therapy Success in Addition to CYP2A6?

Z. Verde
1   Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain
4   denotes equal contributions.
,
C. Santiago
1   Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain
4   denotes equal contributions.
,
JM. Rodríguez González-Moro
2   Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain
,
P. de Lucas Ramos
2   Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain
,
S. López Martín
2   Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain
,
F. Bandrés
3   Department of ‘Aula de Estudios Avanzados’, Fundación Tejerina, Madrid, Comunidad de Madrid, Spain
,
A. Lucia
1   Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain
4   denotes equal contributions.
,
F. Gómez-Gallego
1   Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain
4   denotes equal contributions.
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. Oktober 2013 (online)

Preview

Abstract

Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. The aim of this study was to evaluate the association between the effectiveness of treatment with nicotine or bupropion in heavy smokers (n=70), and 6 candidate polymorphisms in CYP2A6, 5-HTT and HTR2A genes. Analysis revealed a significant association between “favourable” genotype combination carriers (CYP2A6 “slow metabolizer” or 5HTT L-allele or HTR2A-1438GG) and nicotine treatment outcome (OR=2.69, 95% CI=1.28–5.64). Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment.